CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Join us for a LIVE, interactive broadcast on NSCLC Friday 10/5
<< View More Conferences
2017 SUO Annual Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Voss Discusses Neoadjuvant Trials of Immunotherapy in RCC
Dr. Apolo on Managing Toxicities With Checkpoint Inhibitors in Bladder Cancer
Dr. Sonpavde Discusses Current Clinical Trials in Penile Cancer
Oncology Conference Articles
Neoadjuvant Chemotherapy Significantly Improves OS for Low-Risk, Basal Bladder Cancer
Treatment with neoadjuvant chemotherapy prior to radical cystectomy significantly improved overall survival compared with cystectomy alone for patients with the basal subtype of muscle-invasive bladder cancer.
Neoadjuvant Sonidegib Active in High-Risk Prostate Cancer
In a study of neoadjuvant sonidegib in men with high-risk localized prostate cancer undergoing prostatectomy, hedgehog pathway activity was detectable at baseline.
Sensitivity, Resistance of Molecular Subtypes in Prostate Cancer Identified Through Drug Response Scores
Prostate cancer has recently been recognized as a genomically heterogeneous disease with subtypes similar to breast or ovarian cancers.
Checkpoint Inhibitors Hold Promise for BCG-Unresponsive NMIBC
The established efficacy of single-agent checkpoint inhibition for metastatic urothelial carcinoma along with molecule expression analyses suggests that PD-1/PD-L1 inhibition could hold promise for patients with non-muscle invasive bladder cancer, particularly those unresponsive to Bacillus Calmette-Guérin.
MRI, PCA3 Tests Are Reliable Indicators of Prostate Biopsy Positivity
Both magnetic resonance imaging and prostate cancer antigen 3 tests can predict a positive prostate biopsy and are helpful in identifying high-risk prostate cancer.
Plimack Recaps 2017 Immunotherapy Approvals in Bladder Cancer
It has been a landmark year for immunotherapy in bladder cancer with the approval of 5 checkpoint inhibitors across first and second line.
Immunotherapy Combinations on the Rise for RCC
The combination of PD-1 or PD-L1 inhibitors with existing frontline therapies could represent a superior approach for some treatment-naïve patients with renal cell carcinoma.
Plethora of Ongoing Trials Explore Immunotherapy Combinations for Bladder Cancer
Stemming from the wave of checkpoint inhibitor approvals, multiple trials have begun evaluating immunotherapies in combination with other agents for the treatment of patients with advanced bladder cancer.
Immunotherapy Combo Regimens Next Step in Bladder Cancer
Elizabeth Plimack, MD, discusses the impact of the immunotherapy approvals in the first- and second-line setting for bladder cancer and the future of combinations for these patients.
FDA Approval in Hairy Cell Leukemia, NDA in Urothelial Carcinoma, and 2018 ILCA Conference Highlights
FDA Approves Duvelisib for CLL and Follicular Lymphoma
Brigatinib Bests Standard of Care to Improve PFS in Advanced NSCLC
Neoadjuvant Immunotherapy May Change Standard of Care in Early-Stage NSCLC
Repotrectinib Shows Promising Activity in ROS1+ NSCLC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.